Commodore Capital’s Soleno Therapeutics SLNO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-652,432
| Closed | -$21.8M | – | 40 |
|
|
2026
Q1 | $21.8M | Sell |
652,432
-547,568
| -46% | -$21.5M | 1.26% | 23 |
|
|
2025
Q4 | $55.6M | Sell |
1,200,000
-150,000
| -11% | -$8.22M | 3.7% | 12 |
|
|
2025
Q3 | $91.3M | Buy |
1,350,000
+740,000
| +121% | +$54.9M | 4.46% | 8 |
|
|
2025
Q2 | $51.1M | Sell |
610,000
-540,000
| -47% | -$40.4M | 3.61% | 12 |
|
|
2025
Q1 | $82.2M | Sell |
1,150,000
-375,000
| -25% | -$18.3M | 6.05% | 4 |
|
|
2024
Q4 | $68.5M | Buy |
1,525,000
+265,000
| +21% | +$13.7M | 5.02% | 7 |
|
|
2024
Q3 | $63.6M | Sell |
1,260,000
-165,000
| -12% | -$7.9M | 3.98% | 9 |
|
|
2024
Q2 | $58.1M | Buy |
1,425,000
+1,255,467
| +741% | +$53.2M | 3.97% | 8 |
|
|
2024
Q1 | $7.26M | Sell |
169,533
-530,467
| -76% | -$24M | 0.49% | 34 |
|
|
2023
Q4 | $28.2M | Sell |
700,000
-187,500
| -21% | -$5.33M | 2.46% | 15 |
|
|
2023
Q3 | $26.2M | Buy |
+887,500
| New | +$5.37M | 3.06% | 14 |
|
Commodore Capital's SLNO Position: Q2 2026 in Review
Commodore Capital sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 652,432 shares — an estimated $21.8M sold.
Commodore Capital first reported a position in SLNO in Q3 2023 and held it in 11 quarters. The position peaked at $91.3M in Q3 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.
- Commodore Capital reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
- Commodore Capital sold 652,432 Soleno Therapeutics shares in Q2 2026, an estimated $21.8M.
- Commodore Capital first reported a position in Soleno Therapeutics in Q3 2023 and held it in 11 quarters.
- Commodore Capital's Soleno Therapeutics position peaked at $91.3M in Q3 2025.
- 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.
Based on Commodore Capital's 13F filing for Q2 2026, filed 14 Aug 2026.